Guangzhou Wondfo Biotech Co.,Ltd. (300482.SZ) has disclosed its 2025 annual performance forecast, indicating an expected net profit attributable to shareholders of the listed company ranging from 46 million to 69 million yuan, representing a year-on-year decrease of 87.71% to 91.81%.
The company anticipates a net loss after deducting non-recurring gains and losses between 7.5 million and 15 million yuan.
According to the announcement, the decline is primarily attributed to a year-on-year decrease in the company's core business revenue, mainly caused by a drop in domestic income.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments